Yoskowitz Marc J 4

What Happened

• Marc J. Yoskowitz, a non-executive director of Mereo BioPharma Group plc (MREO), was granted awards totaling 162,163 derivative units on 2026-02-26: 66,000 restricted units (reported at $0.00) and 96,163 deferred restricted stock units (DRSUs) reported with price N/A. These are awards/compensation — not open-market purchases or sales.

Key Details

• Transaction date: February 26, 2026; Form 4 filed February 27, 2026 (appears timely).
• Grants: 66,000 units at $0.00; 96,163 units reported as N/A. Total units granted = 162,163.
• Vesting: Vests in substantially equal monthly installments over one year from the grant date (footnote F1 / F3).
• ADS note: Each American Depositary Share (ADS) represents 5 ordinary shares (footnote F2). The 96,163 DRSUs were granted in ADS form per the filing (footnote F3).
• Payment timing: DRSUs paid in ADSs generally 180 days following separation of service (per F3).
• Shares owned after the transaction: not specified in the information provided.

Context

• These are compensation awards (derivative units/DRSUs) to a non-executive director, not open-market buying or selling. DRSUs convert to ADSs under the stated conversion/vesting rules and are typically paid after vesting (and possibly after separation), so they do not represent immediately tradable shares.